BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Long-term Debt

The Long-Term Debt of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 1.39 B CNY. In the previous year, Long-Term Debt was 1.57 B CNY — a change of -11.30% (lower).

Long-term Debt

1.39 BCNY

YoY

-11.30%

Last updated:

Long-Term Debt of BrightGene Bio-Medical Technology Co is 2025 1.39 B CNY. Long-Term Debt of BrightGene Bio-Medical Technology Co was 2024 1.57 B CNY. It decreases by -11.30% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2020
77.52 M CNY
Jan 1, 2021
618.69 M CNY
Jan 1, 2022
1.58 B CNY
Jan 1, 2023
1.61 B CNY
Jan 1, 2024
1.57 B CNY
Jan 1, 2025
1.39 B CNY
The BrightGene Bio-Medical Technology Co Long-term Debt history
YEARLong-term DebtYoY
1.39 BCNY-11.30%
1.57 BCNY-3.07%
1.61 BCNY+2.47%
1.58 BCNY+154.74%
618.69 MCNY+698.15%
77.52 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Long-Term Debt of BrightGene Bio-Medical Technology Co is 1.39 B CNY in 2025.

Long-Term Debt of BrightGene Bio-Medical Technology Co changed from 1.57 B CNY to 1.39 B CNY, representing a -11.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co